title: Medical management of persistent and recurrent cushing disease.
abstract: Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.
authors.affiliation: Department of Medicine, Oregon Health & Science University, Portland, OR 97239, USA. fleseriu@ohsu.edu
authors.forename: Maria
authors.initials: M
authors.lastname: Fleseriu
mesh_terms: D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000517:prevention & control; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D010902:Pituitary Gland / Q000601:surgery*; D011183:Postoperative Complications / Q000188:drug therapy / Q000453:epidemiology; D016896:Treatment Outcome